Lundin J - Search Results

1

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.

Karlsson C, Lundin J, Kimby E, Kennedy B, Moreton P, Hillmen P, Osterborg A. Karlsson C, et al. Among authors: lundin j. Br J Haematol. 2009 Jan;144(1):78-85. doi: 10.1111/j.1365-2141.2008.07451.x. Epub 2008 Oct 30. Br J Haematol. 2009. PMID: 19016731 Free article. Clinical Trial.

2

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A. Lundin J, et al. Blood. 2002 Aug 1;100(3):768-73. doi: 10.1182/blood-2002-01-0159. Blood. 2002. PMID: 12130484 Free article. Clinical Trial.

3

Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia.

Lundin J, Osterborg A. Lundin J, et al. Semin Hematol. 2004 Jul;41(3):234-45. doi: 10.1053/j.seminhematol.2004.05.005. Semin Hematol. 2004. PMID: 15269883 Review.

4

Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.

Lundin J, Karlsson C, Celsing F. Lundin J, et al. Med Oncol. 2006;23(1):137-9. doi: 10.1385/MO:23:3. Med Oncol. 2006. PMID: 16645240

5

Strategies in the management of alemtuzumab-related side effects.

Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H. Osterborg A, et al. Among authors: lundin j. Semin Oncol. 2006 Apr;33(2 Suppl 5):S29-35. doi: 10.1053/j.seminoncol.2006.01.027. Semin Oncol. 2006. PMID: 16720201 Review.

6

Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.

Rezvany MR, Tehrani MJ, Karlsson C, Lundin J, Rabbani H, Osterborg A, Mellstedt H. Rezvany MR, et al. Among authors: lundin j. Br J Haematol. 2006 Nov;135(4):475-85. doi: 10.1111/j.1365-2141.2006.06324.x. Epub 2006 Sep 22. Br J Haematol. 2006. PMID: 16995884 Free article. Clinical Trial.

7

Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia.

Norin S, Kimby E, Lundin J. Norin S, et al. Among authors: lundin j. Med Oncol. 2010 Sep;27(3):820-5. doi: 10.1007/s12032-009-9292-y. Epub 2009 Aug 25. Med Oncol. 2010. PMID: 19705305

8

Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.

Osterborg A, Karlsson C, Lundin J. Osterborg A, et al. Among authors: lundin j. Curr Hematol Malig Rep. 2009 Jan;4(1):47-53. doi: 10.1007/s11899-009-0007-4. Curr Hematol Malig Rep. 2009. PMID: 20425438 Review.

9

Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.

Sylvan SE, Rossmann E, Mozaffari F, Porwit A, Norin S, Karlsson C, Hansson L, Lundin J, Österborg A. Sylvan SE, et al. Among authors: lundin j. Br J Haematol. 2012 Dec;159(5):608-12. doi: 10.1111/bjh.12077. Epub 2012 Oct 9. Br J Haematol. 2012. PMID: 23043283 Free article. Clinical Trial. No abstract available.

10

Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.

Eketorp Sylvan S, Hansson L, Karlsson C, Norin S, Lundin J, Osterborg A. Eketorp Sylvan S, et al. Among authors: lundin j. Leuk Lymphoma. 2014 Aug;55(8):1774-80. doi: 10.3109/10428194.2013.827786. Epub 2014 Feb 4. Leuk Lymphoma. 2014. PMID: 24237446

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

302 results

Search Page

Filters